Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.87B 50.5B 47.37B 88.99B 6,016B 89.87B 597B 233B 2,946B 239B 234B 10,195B	P/E Ratio 2018	-8.76x	P/E Ratio 2019	-11.9x
Enterprise Value	80.96B 69.78B 64.22B 60.25B 113B 7,652B 114B 759B 297B 3,747B 304B 297B 12,966B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
27/06/24	Allergan Aesthetics Debuts Alle Payment Plans	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Actavis PLC Share Price NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	30/11/2016
Robert Michael PSD	President	55	07/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	07/05/2020
Scott Reents BRD	Director/Board Member	-	07/05/2020
Ryan Quigley BRD	Director/Board Member	-	07/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.11%	-1.81%	+39.72%	+148.57%	1,010B
JOHNSON & JOHNSON	-1.70%	+1.87%	+52.36%	+44.44%	580B
ABBVIE INC.	-2.42%	-0.38%	+16.43%	+63.53%	402B
ROCHE HOLDING AG	-0.46%	0.00%	+21.28%	+19.14%	330B
NOVARTIS AG	-1.52%	+2.45%	+24.75%	+33.03%	281B
ASTRAZENECA PLC	-1.95%	-4.32%	+22.02%	+12.96%	280B
NOVO NORDISK A/S	-0.57%	+5.00%	-42.66%	-48.28%	197B
AMGEN INC.	-0.04%	+3.06%	+20.56%	+55.98%	192B
GILEAD SCIENCES, INC.	-0.35%	-2.97%	+12.14%	+57.33%	156B
Average	-0.93%	+0.84%	+18.51%	+42.97%	380.97B
Weighted average by Cap.	-0.96%	+1.04%	+27.61%	+67.32%

	2018	2019
Net sales	15.79B 13.61B 12.52B 11.75B 22.07B 1,492B 22.29B 148B 57.83B 731B 59.25B 57.99B 2,528B	16.09B 13.87B 12.76B 11.97B 22.49B 1,521B 22.71B 151B 58.94B 745B 60.38B 59.1B 2,577B
Net income	-5.1B -4.39B -4.04B -3.79B -7.12B -482B -7.2B -47.79B -18.67B -236B -19.13B -18.72B -816B	-5.27B -4.54B -4.18B -3.92B -7.37B -498B -7.44B -49.43B -19.31B -244B -19.78B -19.36B -844B
Net Debt	21.89B 18.87B 17.36B 16.29B 30.6B 2,069B 30.9B 205B 80.19B 1,013B 82.15B 80.41B 3,506B	17.3B 14.91B 13.73B 12.88B 24.19B 1,635B 24.43B 162B 63.39B 801B 64.94B 63.56B 2,771B

End-of-day quote NYSE Other stock markets
- ^USD	-